Ginkgo Bioworks Holdings, Inc.
DNA NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$9.99
KIRA · Stoqly’s AI analyst, in plain words
- Ginkgo Bioworks Holdings, Inc. had $170M of revenue in fiscal 2025, down 25.1% on the year before. Over five years, revenue changed +17.3% a year on average.
- Its operating margin was −185.3%, up 61.3 pts: of every 100 in sales, about −185 is left after running the business.
- Ginkgo Bioworks Holdings, Inc. lost $313M in fiscal 2025.
- Free cash flow was −$179M in fiscal 2025, −105.0% of revenue.
Market cap
$554M
P/E
—
Revenue
$170M
Net income
−$313M
Free cash flow
−$179M
Operating margin
−185.3%
Ginkgo Bioworks Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−25.1%
No. Sales fell 25.1% last year.
Does it make a profit?
−183.8%
No. It lost money last year.
Does profit turn into cash?
−105.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ginkgo Bioworks Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Ginkgo Bioworks Holdings, Inc.
- CIK
- 0001830214
Ginkgo Bioworks Holdings, Inc. · DNA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $314M | $478M | $251M | $227M | $170M |
| Revenue growth | 309.4% | 52.2% | −47.4% | −9.7% | −25.1% |
| Net interest income | −$9.7M | — | — | — | — |
| Operating margin | −582.6% | −462.4% | −343.8% | −246.5% | −185.3% |
| Net income | −$1.8B | −$2.1B | −$893M | −$547M | −$313M |
| Net margin | −583.1% | −440.6% | −355.1% | −240.9% | −183.8% |
| Diluted EPS | −$1.39 | −$50.20 | −$18.37 | −$10.54 | −$5.64 |
| Cash | |||||
| Cash from operations | −$254M | −$252M | −$296M | −$320M | −$171M |
| Capital expenditure | $56.5M | $52.3M | $40.8M | $62.5M | $7.7M |
| Free cash flow | −$310M | −$304M | −$336M | −$382M | −$179M |
| FCF margin | −98.9% | −63.7% | −133.7% | −168.3% | −105.0% |
| Share count change | 6.7% | −96.9% | 15.8% | 6.8% | 6.9% |
| Debt and strength | |||||
| Cash and short-term investments | $1.6B | $1.3B | $944M | $562M | $423M |
| Loans, net | — | $7.5M | $21.0M | $25.1M | $9.7M |
| Shareholders' equity | $1.5B | $1.7B | $1.1B | $716M | $509M |
| Current ratio | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Interest coverage | −770.5x | −20,839.2x | −9,294.7x | −5,954.9x | — |
| Returns and quality | |||||
| Return on equity | −186.1% | −129.9% | −63.0% | −60.3% | −51.1% |
| Return on tangible equity | −125.1% | −134.5% | −92.5% | −85.0% | −68.7% |
| Piotroski F-score | 3 | 4 | 2 | 3 | 2 |
| Altman Z'' | −1.4 | −5.9 | −8.5 | −13.1 | −16.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.5M
5 insiders
Of sales under plans
1%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ginkgo Bioworks Holdings, Inc. · DNA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.99 a share, the company is worth $554M.
Source: SEC EDGAR XBRL filings (CIK 0001830214). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.